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resumo 
 
 
O presente relatório destina-se a descrever as atividades 
desenvolvidas no âmbito do estágio curricular que teve lugar na 
empresa Datamédica, Serviços e Consultoria em Bioestatística, 
Lda., uma Contract Research Organization (CRO). O estágio 
teve a duração de 8 meses durante os quais a estagiária 
desempenhou funções de CRA sendo o principal foco a 
monitorização dos ensaios clínicos. Para além da principal 
atividade, foram ainda desenvolvidas funções em áreas 
adjacentes à investigação clínica, tais como CTA e Medical 
Writing. 
 
Este trabalho tenta mostrar a visão obtida e os pontos de vista 
da estagiária enquanto monitora de ensaios clínicos. 
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abstract 
 
 
This report intends to describe the activities carried out under 
the traineeship which took place in the company Datamédica, 
Biostatistics Services and Consulting, Inc., a Contract Research 
Organization (CRO). The internship had the duration of 8 
months during which the trainee worked as CRA being the main 
focus the monitoring of clinical trials. Besides the main activity, 
have also been developed functions adjacent to the clinical 
research, such as CTA and Medical Writing areas. 
This document tries to show the obtained vision and the points 
of view of the trainee while monitoring clinical trials. 
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1.  INTRODUCTION 
 
 
 
This internship report is an integrant part of a second year Master Degree in Pharmaceutical 
Medicine and intends to describe the learning outcomes achieved and the activities performed 
during the curricular training on clinical trials monitoring. The company that has welcomed me was 
Datamédica, Consultoria e Serviços em Biostatística,  Lda.,  a  full  service  contract  research  
organization  (CRO)  placed  in Lisbon. 
From October 2013 to May 2014 it was developed the “on job training” where the main focus was 
clinical trial monitoring along with several working areas linked to clinical research such as quality 
management; data management; medical writing and pharmacovigilance. The internship 
consisted of two different strands of work: the on- site monitoring and the remote monitoring along 
with other office based activities. 
The leading aim of this training report is to describe my experience at Datamédica, Lda., In order 
to evaluate and appraise the performance during the training, it was settled the following learning 
outcomes to be accomplished during the internship: 
Primary objectives: 
 To gain experience on the field of clinical research with expertise in clinical trials 
monitoring alongside with all the intrinsic competences to work through the clinical trial 
conduction particularly on the development and regulatory processes; 
 
 To obtain professional experience by integrating  a clinical operations team inside the 
company which will allow to acquire soft skills that are needed to go further on the 
pharmaceutical industry/work market; 
Secondary objectives: 
 To consolidate and be able to apply the theoretical knowledge assimilated during the 
Master’s degree; 
 
 To go through the company functional dynamics and understand the business model of 
pharmaceutical industry; 
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 To improve the management of interpersonal skills and to strengthen team building and 
team working skills. 
This training report is organized in several chapters chained in a logical manner to ease the 
access of all: 
 In  the  first  chapter,  the  introduction, is  presented  the  context  and  the motivation of 
this report as well as a brief note about the host institution; it is described the objectives 
and the structure of the document; 
 In the second chapter, the State of the art, in this chapter the activities that were 
developed during the training ship are describe and they are divided into two sections, one 
concerning the specific monitoring training and other related to other clinical research 
related activities.  
 In the third chapter, On-the-job-monitoring, are described the activities performed during 
the internship. These activities are separated from the specific training on clinical 
monitoring and the generic training which contains activities in different areas.  
 In the fourth chapter, the discussion, are evaluated the competences and know-how 
acquired during the internship; 
 In the fifth and last chapter are made the conclusions about this training report. 
 
 
1.1. VISION OF THE HOST INSTITUTION 
 
Established on 1996, Datamédica, Lda. counts with over 18 years of experience on the clinical 
research field. Based in Lisbon, it was funded by a group of people with solid knowledge starting 
with a strong evidence of biostatistics work. With the aging of the company, the growth was 
inevitable because it was mandatory reply to the market needs, and so it expanded itself to new 
areas of research leading to the expertise of clinical trials. 
The company is organized by strategic and specialist departments so their employees have 
autonomy and uniformity of decisions. All employees are carefully selected to be suitable for the 
working team and able to respond quickly to the needs of the same. The modus operandi in which 
the company is based is on good teamwork and maintaining good interpersonal relationships 
because without a good individual performance is impossible a good team performance. 
As a full service CRO, Datamédica offers a panoply of services during all the stages of drug 
development such as Pharmacoeconomics; Pharmacoepidemiology; Bioinformatics; Biostatistics; 
Medical Writing; Quality Management; Pharmacovigilance and, of course, Clinical Trials 
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Monitoring. These areas also include solutions and partnerships in Regulatory affairs; Product 
Promotion; Protocol Development and Statistical Analysis. More specifically, inside the clinical 
development and monitoring, the company is able to perform different and complementary 
activities: Protocol and Case Report Form (CRF) design, study start-up and site intelligence tasks; 
study monitoring; study reports and analysis. 
The organizational structure allows the company to respond to customer needs due to 
individualized basis that are treated the solutions for specific shortcomings of the customers. 
At  the  moment  the  therapeutic  areas  of  research  are  cardiology,  rheumatology, urology, 
ophthalmology and oncology. The majority of the clinical trials is phase II/III and is mainly in 
oncology – breast cancer. More lately, Datamédica, Lda. assumed the leading of pharmaceutical 
market on emergent countries as Angola and Mozambique and recently Brazil. They are on road 
to be the prevalent health care provider as well as the development of clinical research.(1) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Structural Organization of Datamédica, Lda.(2) 
 
 
4 
 
2.  STATE OF THE ART 
 
 
 
Clinical trials are a set of procedures in medical research and drug development that are 
conducted to allow safety (or more specifically, information about adverse drug reactions 
and adverse effects of treatments) and efficacy data to be collected for health 
interventions (e.g., drugs, diagnostics, devices, therapy protocols). These trials can take 
place only after satisfactory information has been gathered on the quality of the non-
clinical safety, and Health Authority/Ethics Committee approval is granted in the country 
where the trial is taking place.(3) 
There are different types of trial designs. The parallel design is the most common, is 
more simple and robust; the duration is less than in other designs; allows straight 
forward statistical analysis. The Cross-over designs are the second ones more used, are 
supported by regulatory authorities; the inter-subject variability does not contribute to the 
error variability. And finally the factorial design, which is less common, are used when is 
aim to evaluate more than one intervention in a single experiment.(3) 
These designs also vary with the stage of development in which it is the drug. The trials 
can be phase I, II, III or IV (please see figure 2). The type of trial can be determined by 
considering that pilot studies, pivotal studies (randomized, controlled), and post-
marketing studies (registries) are used to achieve different outcomes.(3)(4) 
 
 
 
 
 
 
 
Figure 2 - Correlation between development phases and types of clinical studies.(5) 
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Obviously the choice of trial design cannot be taken lightly and can be an option too 
complicated as it is necessary to take into account several factors such as intended 
statistical analysis; study endpoints; nature of the study; patients target; selection 
criteria, randomization, blinding/open label procedures, control groups, clinical 
interventions to be made; estimated duration of the trial (please see figure 3 and 4).(3)(4) 
There is still another approach to the study designs which have been increasingly 
supported by regulatory authorities, which are adaptive design trials. One important 
characteristic of adaptive design alludes to the prospectively planned changes, that is, 
the alterations of the trial design are previously planned based on prospectively defined 
time points within the  study so that the existent data would be analyzed and alterations 
made. There are a number of characteristics that can be changed at the time of the 
Interim analysis. Sometimes, it can happen that a study modification was a response to 
an unanticipated event, so not all adaptive modifications are planned.(4) 
 
Figure 3 – The current research process.(6) 
 
 
 Figure 4 - What the research process might look like in 2020.(6) 
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2.1. APPLICABLE LEGISLATION AND REGULATORY FRAMEWORK 
A clinical trial is defined by the ICH-GCP as “any investigation in human subjects 
intended to discover or verify the clinical, pharmacological and/or other 
pharmacodynamics effects of an investigational product(s), and/or to identify any 
adverse reactions to an investigational product(s), and/or to study absorption, 
distribution, metabolism, and excretion of an investigational product(s) with the object of 
ascertaining its safety and/or efficacy.”(3) 
The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use – ICH - is an exceptional project that 
was established in 1990. It brings together the regulatory authorities of Europe, Japan 
and the United States and experts from the pharmaceutical industry in the three regions 
to discuss scientific and technical aspects of product registration.(7)  
The mission aims to create a single set of technical requirements for the registration of 
new drug products and achieve greater harmonization in the interpretation of guidelines 
and requirements for product registration, and hence minimize duplication of testing and 
reporting during the I&D process. It also claims to a better management of human, 
animal and material use of resources and to streamline the development process 
maintaining, always, the quality, safety and efficacy of medical products.(8)  
This project was created to meet a need that was accurate to have a “golden standard” 
with regard to the development of new drugs, especially in key aspects of safety, efficacy 
and quality. These platitudes are essential to make credible and viable medicines, not 
only in the eyes of the authorities but also to the patients and the entire scientific 
community.(7)   
Therefore, the Pharmaceutical Industry has several reasons to support ICH initiative and 
its persistent efforts to further harmonize the technical requirements for the registration 
of innovative drugs. The first one is the reduction of development times and resources by 
providing guidance and prevents clinical trial duplication. ICH also allows an easier 
introduction on the market of several countries, especially in ICH regions. This process 
will simplify inter and intra company globalization since implantation of ICH guidelines, 
which are recognize as a standard.(9)(10)  
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Since there are a lot of regulatory procedures of different regulatory authorities to be 
followed when conducting CT, It is important to point the main aspects to take into 
account when driving clinical trials. In order to run clinical trials in medical products for 
human use, the outcome regulatory strategy should be an approximation of all the rules 
regarding legislation, regulatory and administrative issues, as well as the Good Clinical 
Practices should be applied.(11)  
Before performing a clinical trial, a Clinical Trial Authorization (CTA) should be requested 
and approved. The first step, even before this submission, is acquiring an EudraCT 
number. This number is exclusive and will identify the trial, whether it is performed in one 
or multiple centres. Then the request is submitted to the authorities including already the 
EudraCT number, the protocol number and information about the pretended clinical trial 
such as the name of the study and relevant particularities.(11)  
Before proceeding to the clinical trial itself, it is mandatory to have an approved 
authorization by the Ethics Committee. The process could be done before or at the same 
time as the submission to the authorities. In Portugal, this entity is CEIC (Comissão de 
Ética para a Investigação Clínica). A requirement is presented to CEIC, which will 
approve or disapprove the trial, based on the submitted information, on its conception 
and pertinence, a convenient risk-benefit, among other criteria. The requirement form 
may be composed by two modules: the first module is common in all the member-
estates, and it is the only one requested in Portugal. The decision should be 
communicated in a maximum of 60 days after the reception of the request. One approval 
request will be considered valid if it fulfils the specific criteria on the administrative 
information required, such as the EudraCT confirmation document, the requirement 
itself, the request form, the investigator’s brochure, information on the experimental drug, 
the summary of product characteristics, and a list of the authorities where the 
submission was performed. Additional information about eventual special situations 
should also be present.(12)  
In Portugal, specifically, the requirement should be written in Portuguese, and there is a 
set of specifications regarding the participants, the protocol, the investigational medical 
product, installations and personnel, and financial subjects.  
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2.2. CLINICAL RESEARCH IN PORTUGAL  
 
While the picture of crisis is general, Portugal was affected in a very overwhelming way 
and scenery for clinical research is not the best, principally to conduct clinical trials. 
According to INFARMED data, over the last 5 years there has been a marked decrease 
in the number of clinical trials conducted in Portugal.(13) 
Table 1 – Decrease of Clinical Trials by phase.(14) 
Phase 2007 2011 
Phase I 7 6 
Phase II 30 19 
Phase III 74 58 
Phase IV 21 5 
Total 132 88 
 
Since 2007 to 2011, the total number of CT submissions decreased from 136 to 88, 
which corresponds to an approximate 35% reduction on total submissions as showed on 
table 2. Overall, phase III presents the most volume of clinical trials submissions.(14) 
The average decision time performed by INFARMED improved through the years. It 
started with 45 days of average decision time in 2007 and decreased to 41 in 2011. 
Further data from INFARMED related to last year, 2012, showed that were 86 clinical 
trial applications submitted and from those only 76 were approved. So, the landscape for 
clinical trials in Portugal is getting worse, year after year.(14) 
Data from an APIFARMA’s study in 2009 showed that Portugal are conducted less 55%  
CT  compared  with  Belgium,  a  country  with  an  equivalent  dimension.  This 
difference is responsible for a loss of approximately 136 million euro that could be 
invested in the research units and in the creation of jobs positions in companies and 
research sites.(13) 
It is also important to highlight that the number of trials initiated by academic researchers 
is decreasing in Portugal, contrary to the European trend. 
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Table 2 – Decrease of Clinical Trials by phase.(14) 
Clinical Trial applications 
(CTA) 
2007 2008 2009 2010 2011 
CTA Submitted 136 146 116 107 88 
CTA Authorized 131 138 116 105 87 
CTA Not Authorized 0 0 0 2 0 
Average time for authorization (days) 45 43 42 42 41 
 
Although, in 2013 were evaluated and authorized 116 clinical trial authorization requests, 
which is an increase of 17 % compared to 2012. As per clinical trial, the average 
assessment time was 38 days, 5 %, lower than in 2012, with about 99 % of the 
evaluated processes and concluded fulfilled the statutory period (60 days).(17) 
Despite the difficulties mentioned above, there are also some that can play in favor of 
Portugal and make our country a more attractive place for the clinical trials community. 
Portugal has lots of professionals willing to enter or remain in the area of clinical 
research. We, therefore, have a scientific mass considerable to work in this area. Just 
missing some specific training for people to be made aware of the needs of most clinical 
trials, but despite this over the years have formed main investigators with some 
prominence at the time.(15)  
Although it is necessary to develop qualified sites, already in Portugal there are some 
that stand out for their competence and responsibility. With the right investment quickly 
became sites of excellence that will bring Portugal recognition and competitiveness that 
so many crave.(15) 
Portugal is successful in some therapeutic areas such as oncology, cardiology, 
neurology and therefore is a unique opportunity to establish sites of excellence in 
Portugal for these therapeutic areas.(14) 
There are very good partnerships between academia and industry that need to be 
leveraged. The Health Cluster Portugal is a good sample of how partnerships can be 
developed, and Portugal can be a competitive player in the research, design, 
development, manufacture and marketing of products and services related to health.(15)  
10 
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3.  ON-THE-JOB TRAINING 
Given the urgent need to create professionals and educated workforce for meeting 
the demands of pharmaceutical industry, the opportunity of an internship drives to a 
better preparation for those wishing to integrate clinical research.  
The traineeship included a junction of several areas of clinical research allowing 
different experiences what was broadcast in a higher gain of knowledge. 
In this chapter I will provide a detailed description of the procedures followed during 
the internship to perform the requested tasks and activities and introduce the different 
areas of work. This way, the current chapter is divided in 2 main sections: the specific 
training and other clinical research related activities. Each subsection is a more 
detailed description of the activities developed.  
 
3.1. SPECIFIC TRAINING: CLINICAL MONITORING  
 
3.1.1. THE CRA ROLE 
Clinical trial monitoring was the main reason that leads this internship to be 
accomplished within the experience of Datamédica, Lda. It was also the major area of 
interest and motivation of the trainee. 
It was an interesting challenge and intimidating to some extent since it is an area of 
great importance in clinical research, where much money is invested and bright and 
overwhelming results are expected. As of high importance for the health of patients, 
this was one of the main reasons why I decided to embark on this area. The fact that 
it may be contributing to change for better the health and life of a person means a lot 
to me. It is also true that scared me a little at first because I did not want and could 
not have margin for error to be dealing with so important therapeutic areas. 
When I was integrated into the clinical investigation department as a CRA trainee, it 
was allocated to me four Oncology clinical studies in breast cancer and one in 
Diabetic Retinopathy. When I came across studies in oncology I realized I was not 
beside a clinical area that would be easy since it would require a lot of me, especially 
in the knowledge of pathophysiology because only then could follow and understand 
the protocol of each study. In all of them I assumed functions of CRA and Clinical Trial 
Assistant – CTA always with the supervision of my Clinical Operations Director. 
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As part of my integration on the company, the first step was doing a self-training on 
their standard operating procedures (SOPs), especially on the SOPs related with the 
Quality and Clinical departments. 
The function for which I was trained, CRA, requires and compels to have a very active 
role in guiding and leading the clinical trial. It has to be the ability of motivate and 
organize the study team as well as a leading role in planning, coordinating and 
monitoring all the study procedures. It also is necessary to have a bunch of profile 
characteristics that are the key to achieve success on managing interpersonal 
relationships, since all the studies were performed by multicultural and 
multidisciplinary team members. Essentially, the main focus of the CRA work is 
checking that the safety of the subjects is paramount; is the main line of 
communication between the sites and the sponsor; performs site management not 
only on-site but also from the office (in-house management); review study data from 
the subjects and verifying it against source data and collecting for processing; Liaising 
with ethics committee and regulatory authorities, internal departments and suppliers.  
 
3.1.2. SITE START-UP: FEASIBILITY AND SELECTION 
Site selection requires that the sponsor can ensure that the trial will take place 
according to planned; the site has properly qualified professionals; there are enough 
patients to be recruited to the study; these patients meet the inclusion/exclusion 
criteria; that study will take place in compliance with the protocol; that the site is able 
to perform the required clinical assessments. 
Clinical trial site selection is important to getting the right data. There are some 
important considerations to taking on count in site selection, like: qualifications and 
experience of the principal investigator, study site coordinator and all the research 
team; suitability of patient population; existence of qualified equipment for diagnostic 
and therapeutic; feedback from previous trials and historic of recruitment rates; 
geographic location; Timing of Institutional Review Board meetings Contractual and 
budgetary negotiations. 
 
3.1.3. SUBMISSION TO COMPETENT AUTHORITIES 
To begin the complex process of conducting a clinical trial is necessary to obtain all 
required documentation by National and European authorities that are legally required 
to sponsors.  
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According to the Portuguese Law 21/2014 of April 16th, when a sponsor wants to 
perform a clinical trial in Portugal it is mandatory to obtain the authorization of 
INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.) which 
is the Regulatory Authority in Portugal and the Favorable Opinion from CEIC 
(Comissão de Ética para a Investigação Clínica) which is the National Ethics 
Committee for Clinical Research. (16) 
The first step to be taken is the request of EudraCT number. This number is a unique 
identification of the trial in question and must be obtained through the registration in 
the European Clinical Trials’ database. The applicant, who may be the sponsor or his 
representative, will have to fill out a form with some information about the trial. 
EudraCT is a large European database that provides the authorities with the 
necessary information to communicate and oversee clinical trials and drug 
development. After registration and obtaining EudraCT number, the next step is to 
create the XML file that is required for study submission to the competent authorities. 
The XML file, also known as “Annex 1 – Application Form: Request For Authorization 
Of A Clinical Trial On  A  Medicinal  Product  for  Human  Use  To  The  Competent  
Authorities  And  For Opinion Of The Ethics Committees In The Community”, is a key 
point about the whole study because it contains all the information necessary for their 
identification.  
The sponsor is now ready to perform the clinical trial application to the Portuguese 
Competent Authorities. This application can be made in parallel. 
For the submission to INFARMED, the applicant must comply with the information 
provided by the Authority “Instructions to the Applicants of a Clinical Trial Application” 
present on his website. In parallel, for the submission to CEIC it is also necessary 
meet the terms present on the guidance “Instructions to the Applicants for the 
submission of an opinion request to CEIC”. For these two submissions it is important 
to know that they follow the same line of approval. They undergo through sequential 
phases: the validation; the additional information request and deliberation phase. The 
authorities have 30 working days according to the recent law 21/2014 of April 16th to 
achieve a deliberation about the study. If questions are raised by them at the phase of 
additional information request, the clock stops and the applicant has 30 working days 
to reply. Both submissions are made in mixed format: paper and electronic.(16) 
Additionally, it is necessary to notify the treatment of data used in the trial to the 
National Commission for Data Protection (CNPD). For this it is needed to fill a form 
with the variables that will be collected on personal and clinical data of patients. The 
CNPD is an independent body with powers of authority, which operates within the 
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National Assembly. Its generic assignment is to control and supervise the processing 
of personal data, with strict respect for human rights and fundamental freedoms and 
guarantees enshrined in the Constitution and the law. The Commission is the 
National Supervisory Authority for Personal Data. The CNPD cooperates with the 
supervisory authorities for data protection in other states, especially in defense and 
exercise of the rights of people living abroad.  
To conduct a clinical trial, an authorization request to this organism must be sent, as it 
needs approval to automatically manage the private data. CNPD will authorize the 
data management, as long as the following requirements are met:  
 The sponsor will not be able to access the data possessed by the investigator 
that can identify the patients;  
 The data should be compiled in a way that their owners cannot be identified;  
 At the moment that the owners give their permission to conduct the clinical 
trials they should also authorize the automatic management of their data and 
be clearly notified of the purpose and destination of collected files.  
During  the  internship  I  had  the  opportunity  of  being  part  of  three  new clinical  
trial applications for three different studies. I also performed several substantial and 
non- substantial amendments. It is important to note that every time that is needed to 
undertake a substantial amendment to the trial is necessary to submit the amendment 
for approval to the Competent Authorities, which can happen with some frequency 
since clinical trials are subject to change and adapt to a better design or criteria that 
benefit patients and research. The main difference between them is that for one to be 
considering as “substantial” it has to be likely to have significant impact on the 
patient’s safety, mental and physical integrity or on the scientific value of the study. 
The substantial amendments that I had performed were made on the scope of a 
change on the  Principal  Investigator;  the  addiction  of  another  study site  in  
Portugal  and  the addiction of another arm to the study protocol. 
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Table 3 – Substantial and Non-Substantial amendments requirements.(11) 
 
Substantial Non-Substantial 
 Change of main objective of the 
 
CT; 
 
 Change of primary or secondary 
endpoint which is likely to have a 
significant impact on the safety or 
scientific value of the CT; 
 
 Addition of a trial arm or placebo 
group; 
 
 Change of IMPs,  IMPs dosing or 
 
IMPs mode of administration; 
 
 Change of study design which is 
likely to have a significant impact 
on primary or major secondary 
statistical analysis or the 
risk/benefit assessment. 
 Changes to the identification of 
the trial (change of title, etc.); 
 
 
 The addition/deletion of 
exploratory/tertiary endpoints; 
 
 
 A minor increase in the duration of 
the trial (<10% of the overall time 
of the trial); 
 
 Minor clarifications to the protocol; 
 
 
 
 
 
 Correction of typographical errors. 
 
 
For the submission of substantial amendments to the authorities it is necessary to 
evaluate which are the documents that are involved on the amendment and then 
submit the new documents or the new versions with the changes in highlighted 
format. Then, it is followed the same logic of the clinical trial applications: it is needed 
to submit in paper format the cover letter; the proof of fee payment (receipt of 
payment) and the amendment notification form. And in electronic format the changed 
informative elements; the supportive information changes and the XML file updated (if 
applicable). 
In order to obtain the site’s approval for the implementation and execution of a clinical 
trial it is necessary to make a submission to the Hospital or site Administrative Board 
Review. The first step is to gather the documents or requirements that are needed 
and that may depend and vary according to the site. It is also important to understand 
if this submission can be made in parallel or only after getting the INFARMED’s 
approval and CEIC’s favorable opinion, as is requested by several sites. 
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3.1.4. MONITORING VISITS 
According to Law 21/2014, April 16th, the monitoring person (commonly designated 
by CRA) is responsible for guarantying that the data is correctly and completely 
recorded and verifies if the storage, distribution and returning of and documentation of 
the materials under research comply with the good clinical practices. To do this, CRAs 
perform Source Data Verification (SDV) which is the act of compare the data present 
in source documents against data registered in the Case Report Forms (CRFs). The 
sponsor usually defines the number of visits performed during the clinical trial. There 
are different types of site visits: site selection, initiation, monitoring and close-out.(16)   
3.1.4.1. SIV – SITE INITIATION VISITS 
The Site Initiation Visit (SIV) is a crucial visit to the development of the study. It is 
most alike a kick-off meeting of a project because it involves all the “stakeholders” 
related to them. In this specific scenario, it involves all study team of the site and the 
necessary representatives of the study: the CRA and sometimes the Clinical Project 
Manager, Clinical Operations Director and the Medical Director.  
During the SIV the CRA performs a clinical trial presentation which must cover the 
following topics: protocol review; study design; inclusion/exclusion criteria; 
investigational treatment; schedule procedures and visit assessments; 
suppliers/vendors involved; GCPs and AE&SAE reporting. This communication serves 
to ensure that the investigators and study team are aware of their responsibilities and 
obligations regarding the trial and have the adequate facilities and trained team to do 
so.  
As all site visits, this on needs to be prepared with much anticipation because is 
essential to have all set-up at the SIV date to initiate the study. So that is necessary to 
prepare all the folders/binders as the Investigators Site Folder (ISF), the Pharmacy 
Folder and the Patient Folders; make sure that all supplies (e.g. lab supply; CRFs; 
exams machines; etc.) will arrive to site on time as well as the Investigational 
Medicinal Product (IMP). Prior to SIV I needed to fill up and sign a form designed by 
“Green Light Form” which was the confirmation of the readiness of all trial related 
procedures that had to be ready for initiation and posterior inclusion of patients.  
3.1.4.2. MONITORING VISITS 
For the monitoring purpose, all source data must be available for monitoring by the 
sponsor (or its designees), inspections or audits of Health Authorities. Source data 
can be defined as all comprised of documents that are the first point of entry of 
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patient’s medical records or certified copies of original handwritten or electronic data.  
According to ICH-GCP, source documents are “original documents, data, and records 
(e.g., hospital records, clinical and office charts, laboratory notes, memoranda, 
subject’s diaries or evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, copies or transcriptions certified after verification as 
being accurate copies, microfiches, photographic negatives, microfilm or magnetic 
media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and 
at medico-technical departments involved in the clinical trial)”.(11)  
It should be accurate, legible, and up-to-date of patient visits. Each study site should 
be monitored as early as possible after the first subject has been entered and/or initial 
data from the study have been received in order to check protocol understanding and 
compliance with GCP. It is important to note that at the beginning of the trial, the 
source data should be specified on the Source Data Location Form. Some key points 
that I learned during SDV performing is that recording the same data in more than one 
location is not a good practice and should be avoided in order to not create confused 
and contradicted medical records. Other point to note is that should exist an audit trail 
every time changes are made to source data. These changes need to be documented 
by person and date of change.  
The monitoring visit activities start before the visit itself, by performing the necessary 
activities for the visit (preparing documentation, scheduling the visit with the 
investigational team, assess the recruitment rate, among others). 
During the visit I have to ensure that all aspect of the trial are compliant with the 
protocol, ICH-GCPs and regulatory requirements. The main time of the visit is 
allocated to eCRF checking and SDV, as mentioned above. It is also necessary to 
verify the maintenance of ISF and Patient Folders, which involves update 
documentation if necessary, check the delegation form and the enrollment of new site 
personnel if so (important to check if they are properly trained before performing any 
trial-related action).  
A visit to the pharmacy should also be done in order to check the specific trial 
requirements related to IMP. The requirements can be drug stock and supplies; 
verifying if the IMP are properly labeled and packaged as per protocol; in the case of 
a double-blind trial assure that emergency code breaks were supplied; IMP 
dispensing to the correct trial subject; return of IMP from the subject and from the site 
to the sponsor; check for eventual temperature deviations and security and 
appropriateness of pharmacy storage facilities. It is also necessary to compare the 
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IMP accountability forms or records to source documents and ensures that all 
quantities are controlled and correct. IMP destruction can be made according to site 
standard procedures or sponsors internal regulations. 
At every monitoring visit is important to confirm patient’s safety, and to do so is 
necessary to verify if any Adverse Event (AE) occurred and if it was registered on the 
eCRF. In case of Serious Adverse Events (SAEs) I need to assure that the event was 
reported to the pharmacovigillance within 24h.  
3.1.4.3. CLOSE-OUT VISITS  
The Site close-out visit is performed after the Last patient last visit (LPLV) occurred 
and SDV was completely done as well as the queries have been answered. Even the 
sites that have not included any patients need to do site close-out activities. This last 
visit can occur under different scenarios: can mean that the trial has ended or that the 
clinical trial site was closed out due to reasons such as elevated number of protocol 
violations or low recruitment rate which did not justify the expenses on keeping the 
site open. The visit can also occur after the database lock, depending of the trial.  
This visit is prepared by revision of the periodic monitoring reports of the site and by 
preparing a list of documents to be archived at the investigator file. During the visit I 
need to ensure that all open monitoring visit issues are closed; collect or schedule the 
collection of non-medication supplies: unused CRFs, patient diaries or extra protocols, 
laboratory materials and, if so, equipment loaned to the site during the trial. The most 
difficult part is the reconciliation of ISF with the correct filled forms and the collection 
of all relevant documents (e.g. monitoring visit log; drug accountability log; site 
personnel training log; authorized signature log, etc.). Is necessary inform the Ethics 
Committee (CEIC) of trial completion.  
During the internship I had the opportunity to perform two close-out visits. It was a 
tiresome experience because I need to fill a lot of “File notes” explaining why some 
documents were missing and it toke a few hours to get all the essential documents 
together and prepare the ISF closure.  
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3.2. OTHER CLINICAL RESEARCH RELATED ACTIVITIES 
During my internship at Datamedica I had the opportunity to learn and to explore 
different areas related to clinical research.  These activities are integrated on the 
cluster of services data the company has to offer for pharmaceutical industry clients. It 
was very interesting for me take the lead on different areas beside the CRA role but 
that in a certain way contribute to complement my knowledge of the industry 
dynamics. 
3.2.1. OBSERVATIONAL STUDIES 
I had the opportunity of being enrolled on an observational study that was promoted 
by the Portuguese Society of Nephrology named ODYSSEY study: “observational 
study on harmonization of practice patterns and clinical outcomes in haemodialysis”. 
The design of the study was a prospective cohort study based on the collection of 
observational longitudinal data of all incident patients from a representative and 
random sample of units in the country. It was a different experience because I went to 
the haemodialysis units to perform monitoring as well but the scenario of 
observational studies is a bit different from the interventional ones. I was in charge of 
collect the patient data and posteriorly do some database entry, which toke me a long 
period of time. I consider a fruitful experience because I was not aware for the reality 
of haemodialysis patients and this study will help physicians to select the best 
treatment approach based on the clinical practice guidelines and outcomes in the 
future. This study enrolled around 1200 patients from 30 different units distributed in 
all country and has the duration of 5 years. 
3.2.2. MEDICAL WRITING 
Medical Writing involves a set of activities related to the communication process of 
clinical and scientific data. I have taken part in some activities such as elaborating a 
protocol synopsis, reviewing a study protocol and developing informed consent forms. 
These activities gave me an insight of the work needed to prepare the scientific 
rationale for a clinical study and correctly design scientifically valid study protocols.  
3.2.3. QUALITY AND AUDITS 
Quality is a key factor for a good development of clinical trial related activities. If the 
trial is not based on a good quality system the data cannot be consider accurate and 
reliable. One of the tasks that I participated in was the reformulation and 
reorganization of the Standard Operations Procedures (SOPs) and the Quality Manual 
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review. I also had the opportunity of taking part of an audit from a client. The client 
was an American Biotech named Puma Biotechnology, Inc., and the purpose of the 
audit was to verify evaluate if the CRO had the expected requirements to perform the 
monitoring of the trial in Portugal. This experience was one of my favorites because it 
was really difficult to make through but very productive and educational. The audit 
activity started few months earlier because it was necessary to prepare all the 
documentation, update the internal quality requirements and make sure that all 
procedures of the trial were followed through the indications of the sponsor. The audit 
itself last for an entire day, where the auditor, an element of the Global Clinical Trial 
Team, and two other persons from the sponsor’s quality department were present and 
conducted the audit. At the end of the day we received their feedback and some 
corrective actions to implement.  
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4.  DISCUSSION 
 
This chapter presents the discussion of the features of the internship activities 
developed and my point of view of the outcomes and objectives achieved. 
Having the opportunity of taking part in a clinical trials team was a pleasing 
experience, not only because of my professional growth but also because allowed me 
to face some adversities and learn how to overcome daily obstacles which made me 
growth individually and personally.  
When I first contacted with the clinical trials reality I was very optimistic and excited 
with the idea of becoming a CRA. I was also a bit nervous with the big responsibility 
of being in charge of monitoring such difficult procedures and complicated trials, 
essentially on oncology trials where the patient survival depends on the development 
and success of the trial. As time passed by and I had more and more contact with the 
sites and team staff I became more aware of  the reality of clinical trials at study sites 
and the impediments and weaknesses of each one of them and I started to realize 
that clinical monitoring was not the reality that I idealized initially. There are several 
factors that can make the site succeed or fail, and that should be taken in account on 
future site feasibilities.  
Several professionals agree that the first and foremost problem shared by clinical 
trials lies in the choice of sites and inadequate management of the project.  In 
multicenter clinical trials, the study sites begin to screening and randomize patients at 
different stages, having sites beginning weeks or months later than others. This 
disagreement is logically connected to an inadequate response to management and 
may even lead to the recruitment failure.  One way to overcome this problem is to 
choose the sites based on some criteria. Should be given appropriate attention to key 
operating variables such as recruitment rates and current protocol patient population 
based on inclusion/exclusion criteria.  Is known that every site overestimate the 
number of patients they can recruit to complete the study. Another point to be 
checked is the awareness and compliance with GCPs by the principal investigator 
and all research team, which must be motivated and available to work on the trial.  
Another point that I learned how to do was the Financial Agreements between sites 
and the sponsors. It was probably my biggest challenge during the internship 
because it is a long and bureaucratic process in which every single detailed of the 
trial part has to be agreed by each part. It is necessary to be aware of the site 
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requirements about clinical trial fees, as well as, already available templates the sites 
may have. It is also important to have input from the investigational team about the 
distribution of the fees amongst them and, to make sure that all involved parties are 
contemplated in the agreement (pharmacy, laboratory if needed, the administration 
board of the site, etc) which means that it is necessary to discuss the contract with all 
these parties to reach a consensus. Some sites are easier to handle when it comes 
to contracts since they have few specific requirements and there is a contact person 
that deals with all contract related activities. But in other cases, the process can take 
months until is finalized which is another fact contributing to the delay of site 
initiation.  
Despite some tasks that I had performed that were more demanding and despite the 
shockwave of the reality of clinical trials, I believe that the hard work was necessary 
and made me grow. And also, I was involved in more positive and excited tasks than 
negative ones. I enjoyed a lot going to sites and talk with study coordinators and 
investigators about the trials and known the site’s environment that is lived by them. 
That made me understand more the “other partner” that are the study teams and 
comprehend better their requirements and their work practices. I realize that the 
relationship established between the study teams and the CRO/sponsor is an 
important component to fluidize the process in order to achieve the timelines 
provided. When relationships are authentic, and based on dedicated trust, when 
there is collaboration between the parties, the results achieved are better and more 
predictable. So to increase the motivation of investigators and research teams, it 
should be more specific the payment of these professionals and should be better 
established between the sponsor and the administration board for this part would not 
be lost in the financial contract. It calls for a standardization of financial contracts 
approved only by one national entity in order to minimize differences and deviations.  
Regardless of how much I learnt during my internship, there are some activities that I 
wish I had done as dealing with Interactive Voice Response System/ Interactive Web 
Response System (IVRS/IWRS) on the trials. I think it would prepare me better to 
future studies, especially on randomization and drug dispensing matters. Other 
activities that I would like to had done are: dealing with SAEs, working with different 
types of eCRFs and different sponsor electronic platforms (e.g. e-TMF; Clinical 
Monitoring Reports platform and study portals, etc.).  
During this experience I could always count with the support of my colleagues and 
my supervisor to motivate me and help me with current doubts. I think we all learnt a 
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lot with each other and evolve as a working team. My interpersonal skills improved 
immensely due to a constant need of communication between my team at CRO, with 
the sites and the sponsors. These last ones were, similarly to study sites, the most 
challenging communications that I had to done. They don’t always understand the 
Portuguese reality and the problems that we had to overcome to accomplish their 
deadlines.  
I can say that I learn a lot with my own mistakes and became even more independent 
and autonomous that I already was. My work profiles progressed from a passive and 
observing point of view towards collaborating leadership. At the end of my internship I 
shared with my colleagues the feeling of achievement and the sense of work done.    
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5.  CONCLUSION 
Overall, I think I achieved the main goal of understanding the CRA role and the 
dynamics of CRO work environment. Now I can say that I know by experience and 
not just by theory how it is the lifestyle of a CRA. I can assure that the routine never 
gets boring because the working days are varied and busy; usually out of the office to 
the sites for up 2 at 3 days per week and the rest of the days are spent managing the 
studies from the office. The secondary goals were also fulfilled although the 
knowledge is a never ending process and I still have some aspects that I need to 
improve on a daily basis, for example my assertiveness skills and better planning and 
prioritization tasks. Despite them and at the end of this experience I feel that I had 
I’ve grown hugely in comparison with my profile at the beginning. 
I am truly grateful at Datamédica for welcomed me and let me be part of their team. 
Although I am no longer working in the company, I wish them a lot of success and 
prosperity.   
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